ZHAO Tian-tian, SHEN Long-ying, PAN Xian-dao. Research progress of leukotriene B4 receptor antagonistsJ. Acta Pharmaceutica Sinica, 2022, 57(10): 3133-3145. DOI: 10.16438/j.0513-4870.2022-0602
Citation: ZHAO Tian-tian, SHEN Long-ying, PAN Xian-dao. Research progress of leukotriene B4 receptor antagonistsJ. Acta Pharmaceutica Sinica, 2022, 57(10): 3133-3145. DOI: 10.16438/j.0513-4870.2022-0602

Research progress of leukotriene B4 receptor antagonists

  • Leukotriene B4 (LTB4) is a proinflammatory lipid mediator that is synthesized by a number of inflammatory cells. Binding of LTB4 to its receptor leukotriene B4 receptor 1 (BLT1) can migrate neutrophils and macrophages to inflammatory sites through chemotaxis and up-regulation of adhesion molecules. Many researches have shown that LTB4-BLT1 axis is related to the occurrence of autoimmune disorders and other inflammatory diseases. Receptor antagonists of LTB4 are thus expected to be useful therapeutics for these diseases. In this review, we briefly describe the biological function of LTB4 and summarize the preclinical and clinical developments of LTB4 receptor antagonists.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return